OSE Immunotherapeutics

reshuffle pipeline target reorganize shift change
Biotech

Ose narrows focus to conserve cash at expense of wider pipeline

Ose Immunotherapeutics is prioritizing its lung cancer med Tedopi and its ulcerative colitis therapy lusvertikimab.
James Waldron Dec 9, 2025 9:41am
A ballpoint pen rests on top of a stack of documents ready for signing

AbbVie hands back phase 1 duties for inflammation drug to Ose

Dec 8, 2025 5:39am
parachute mountains sunset clouds

Former CBER chief Peter Marks leaps to Lilly—Chutes & Ladders

Oct 10, 2025 8:30am